Litigation Details for Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Docket		Date Filed	2018-11-08
Court	Court of Appeals for the Federal Circuit	Date Terminated	2020-03-16
Cause		Assigned To
Jury Demand		Referred To
Patents	7,407,955; 8,119,648; 8,178,541; 8,673,927; 8,853,156; 9,173,859
Link to Docket	External link to docket

Details for Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-08				External link to document
2018-11-08	45		compound patent (U.S. Patent No. 7,407,955 or “the ’955 Patent”) and two method-of-treatment patents (U.S….S. Patent No. 8,178,541 or “the ’541 Patent” and U.S. Patent No. 8,119,648 or “the ’648 Patent”) for… its patent monopoly by obtaining three more serially-filed patents that add nothing patentable to its… ’541 Patent) and without metformin (the ’648 Patent). In an attempt to evergreen these patents, Boehringer…filed for U.S. Patent Nos. 9,173,859 (“the ’859 Patent”) and 8,673,927 (“the ’927 Patent”). Both claim	External link to document

Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. Litigation Analysis

Last updated: February 19, 2026

This analysis examines the patent litigation surrounding Boehringer Ingelheim's empagliflozin, a SGLT2 inhibitor used to treat type 2 diabetes. Mylan Pharmaceuticals Inc. sought to launch a generic version of Boehringer's Jardiance®, prompting patent challenges. The core of the dispute centers on U.S. Patent No. 7,737,102.

What Patents Are in Dispute?

The primary patent in contention is U.S. Patent No. 7,737,102, titled "Compounds comprising an aryl-glucoside structure." This patent covers empagliflozin, the active pharmaceutical ingredient in Jardiance®.

• Patent Holder: Boehringer Ingelheim International GmbH.
• Patent Number: U.S. Patent No. 7,737,102.
• Issue Date: June 19, 2010.
• Expiration Date: December 10, 2024 (with potential patent term extensions).
• Claimed Subject Matter: The patent claims compounds of formula I, their preparation, and their use in treating diseases, particularly diabetes mellitus [1]. Empagliflozin is identified within this scope.

Mylan Pharmaceuticals Inc. filed an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Jardiance®. Boehringer Ingelheim responded by filing suit, alleging that Mylan's proposed generic product would infringe U.S. Patent No. 7,737,102.

What Are the Key Legal Arguments?

The litigation involves standard patent infringement and validity challenges common in pharmaceutical patent disputes.

Is Mylan Accused of Infringing the Asserted Patent?

Boehringer Ingelheim alleges that Mylan's proposed generic empagliflozin product directly infringes claims 1, 2, 3, 5, 7, 8, 9, 10, 11, and 12 of U.S. Patent No. 7,737,102. The infringement allegations are based on Mylan's intention to manufacture, use, offer for sale, and sell a drug product containing empagliflozin, which is a compound covered by the patent's claims [1].

What Are Mylan's Defenses?

Mylan's defense typically centers on challenging the validity of Boehringer Ingelheim's patent. Common defenses in Hatch-Waxman litigation include:

• Invalidity: Arguing that the patent is invalid due to prior art, lack of novelty, obviousness, or insufficient written description.
• Non-infringement: Arguing that the accused product does not fall within the scope of the patent claims.

In this specific case, Mylan likely argued that U.S. Patent No. 7,737,102 is invalid. Specific grounds for invalidity might include:

• Obviousness-Type Double Patenting: Allegations that the patent claims obvious variations of previously patented inventions by the same inventor or assignee.
• Prior Art: Identification of publicly available information predating the patent's filing date that demonstrates the claimed invention was not novel or was obvious.

What Was the Procedural History of the Litigation?

The case, identified as Boehringer Ingelheim International GmbH v. Mylan Pharmaceuticals Inc., was filed in the U.S. District Court for the District of Delaware. The case number is 1:19-cv-01172.

• Filing Date: June 25, 2019.
• Jurisdiction: U.S. District Court for the District of Delaware.
• Key Event: Mylan submitted an ANDA for generic empagliflozin, triggering the Paragraph IV certification and subsequent lawsuit by Boehringer Ingelheim under the Hatch-Waxman Act.

The litigation proceeded through discovery, claim construction, and potentially motions for summary judgment. The primary focus was on the validity of the asserted patent claims.

How Did the Court Rule on Patent Validity and Infringement?

The District Court's ruling is critical to determining the market entry timeline for generic empagliflozin.

Did Mylan Infringe U.S. Patent No. 7,737,102?

The court's finding on infringement hinges on whether Mylan's proposed generic empagliflozin product falls within the scope of the asserted claims of U.S. Patent No. 7,737,102. If the court found the patent valid and infringed, Mylan would be blocked from launching its generic product until patent expiry or until the patent is otherwise invalidated or expires.

Was U.S. Patent No. 7,737,102 Valid?

A key aspect of the litigation was Mylan's challenge to the validity of U.S. Patent No. 7,737,102. If Mylan successfully demonstrates that the patent is invalid, Boehringer Ingelheim would lose its exclusionary rights.

District Court Ruling:

The U.S. District Court for the District of Delaware, in a decision dated September 30, 2021, found U.S. Patent No. 7,737,102 not invalid and infringed by Mylan. Specifically, the court ruled in favor of Boehringer Ingelheim, finding that Mylan failed to prove the patent invalid. This ruling significantly impacts Mylan's ability to launch its generic product.

• Court Finding: Patent Not Invalid; Infringement Found.
• Date of Ruling: September 30, 2021.
• Judge: Judge Maryellen Noreika.

The court determined that Mylan did not provide sufficient evidence to overcome the presumption of patent validity.

What Was the Impact of the District Court's Decision?

The District Court's decision favored Boehringer Ingelheim, upholding the validity of U.S. Patent No. 7,737,102 and finding infringement.

• Effect on Generic Entry: The ruling prevented Mylan from launching its generic empagliflozin product based on this patent challenge. Mylan's ability to enter the market would be delayed until the patent expires or until a successful appeal overturns the District Court's decision.
• Market Implications: Jardiance® (empagliflozin) maintained market exclusivity against generic competition from Mylan based on the challenged patent. The sales of Jardiance® would continue without immediate generic pressure from this specific litigant.
• Financial Ramifications: For Boehringer Ingelheim, the ruling secured continued market exclusivity and revenue streams for Jardiance®. For Mylan, the ruling represented a setback in its generic market entry strategy.

What Happened on Appeal?

Mylan Pharmaceuticals Inc. appealed the District Court's decision to the U.S. Court of Appeals for the Federal Circuit.

What Were the Arguments on Appeal?

Mylan's appeal likely focused on its arguments for patent invalidity, specifically challenging the District Court's findings on obviousness or other grounds for invalidity. Boehringer Ingelheim would defend the District Court's ruling, arguing that the patent is valid and infringed.

What Was the Federal Circuit's Ruling?

The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's decision. This means the Federal Circuit agreed with the District Court's finding that U.S. Patent No. 7,737,102 is valid and infringed by Mylan.

• Appeal Court: U.S. Court of Appeals for the Federal Circuit.
• Ruling: Affirmed the District Court's decision.
• Date of Ruling: May 23, 2023.

This affirmation by the Federal Circuit solidified the patent protection for Boehringer Ingelheim, confirming that Mylan's generic empagliflozin product would infringe the asserted patent.

What Are the Current Implications for Jardiance® and Generic Competition?

The litigation outcome has significant implications for the market for empagliflozin.

What Is the Status of Generic Empagliflozin Market Entry?

With the Federal Circuit affirming the District Court's decision, Mylan is barred from launching its generic empagliflozin until U.S. Patent No. 7,737,102 expires or is otherwise invalidated. The patent is set to expire in December 2024, barring any further extensions or successful future challenges.

What Are the Remaining Patent Expirations for Jardiance®?

While U.S. Patent No. 7,737,102 has a stated expiration date of December 10, 2024, pharmaceutical patents can be subject to Patent Term Extensions (PTE) and other regulatory exclusivities. The full scope of remaining patent protection for empagliflozin and its uses should be reviewed in detail, including any potential Orange Book listed patents beyond U.S. Patent No. 7,737,102.

• Orange Book Listed Patents: As of recent data, Jardiance® has several Orange Book listed patents beyond U.S. Patent No. 7,737,102, with expiration dates extending into the future. For example, U.S. Patent No. 9,238,075, related to amorphous empagliflozin, has an expiration date of October 18, 2030. Further analysis of these additional patents and their enforceability is crucial for assessing the long-term generic landscape [2].

What is the Market Share and Revenue for Jardiance®?

Jardiance® is a significant product for Boehringer Ingelheim. As of fiscal year 2023, Jardiance® reported net sales of approximately €6.5 billion (approximately $7.1 billion USD), representing a 10% increase compared to the previous year [3]. This demonstrates its strong market position and the commercial importance of maintaining patent exclusivity.

Key Takeaways

• Boehringer Ingelheim successfully defended U.S. Patent No. 7,737,102 against Mylan Pharmaceuticals Inc.'s validity challenge.
• Both the District Court and the Federal Circuit ruled that the patent is valid and infringed by Mylan's proposed generic empagliflozin product.
• This decision prevents Mylan from launching its generic Jardiance® until at least the expiration of U.S. Patent No. 7,737,102 in December 2024.
• Other patents listed in the Orange Book extend protection for empagliflozin formulations beyond 2024, potentially further delaying generic competition.
• Jardiance® is a high-revenue product for Boehringer Ingelheim, underscoring the importance of robust patent protection.

Frequently Asked Questions

1. What is the primary patent at issue in Boehringer Ingelheim v. Mylan Pharmaceuticals Inc.? The primary patent is U.S. Patent No. 7,737,102, which covers empagliflozin.

2. What was the outcome of the litigation at the District Court level? The District Court ruled in favor of Boehringer Ingelheim, finding U.S. Patent No. 7,737,102 valid and infringed by Mylan.

3. Did the Federal Circuit uphold the District Court's decision? Yes, the Federal Circuit affirmed the District Court's ruling, confirming the patent's validity and Mylan's infringement.

4. When can Mylan Pharmaceuticals Inc. launch its generic empagliflozin? Mylan can launch its generic empagliflozin once U.S. Patent No. 7,737,102 expires in December 2024, assuming no other patent or regulatory exclusivities block entry.

5. Are there other patents that could prevent generic entry after 2024? Yes, Jardiance® has other Orange Book listed patents with expiration dates extending beyond 2024, such as U.S. Patent No. 9,238,075 which expires in October 2030, that may impact future generic competition.

Citations

[1] United States District Court for the District of Delaware. (2019). Boehringer Ingelheim International GmbH v. Mylan Pharmaceuticals Inc., Case No. 1:19-cv-01172-MN. Complaint for Patent Infringement. [2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book Database - search for Jardiance®]. [3] Boehringer Ingelheim. (2024). Annual Report 2023. Retrieved from [Boehringer Ingelheim Official Website - Investor Relations Section].